ESC 365 - Spironolactone in patients with permanent atrial fibrillation, possible heart failure protective potential.

ESC Premium Access

Spironolactone in patients with permanent atrial fibrillation, possible heart failure protective potential.

Session: Poster Session 4 - Epidemiology of atrial fibrillation, miscellaneous

Topic: Mechanisms for Heart Failure and Cardiac Complications

Speaker: Professor R. Dabrowski (Warsaw, PL)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Rafal Dabrowski

National Institute of Cardiology, Warsaw (Poland)

0 follower

9 more presentations in this session

Circulating biomarkers of myocardial fibrosis and cellular apoptosis in patients with atrial fibrillation and heart failure with preserved ejection fraction

Speaker: Associate Professor M. Dzeshka (Grodno, BY)

Left ventricular stiffness assessed by diastolic wall strain predicts infrequent atrial fibrillation

Speaker: Doctor H. Kishima (Nishinomiya, JP)

Outcomes of heart failure with reduced ejection fraction (HFrEF) status post implantable cardioverter-defibrillator (ICD) presenting with HFrEF exacerbation with verses without atrial fibrillation(AF)

Speaker: Doctor H. Arshad (Newark, US)

The impact of elective cardioversion for atrial fibrillation in heart failure patients

Speaker: Doctor J. Graby (Bath, GB)

MOODS: a novel risk score to identify patients with atrial fibrillation and sleep apnoea

Speaker: Doctor K. Kadhim (Adelaide, AU)

Access the full session

Poster Session 4 - Epidemiology of atrial fibrillation, miscellaneous

Speakers: Professor R. Dabrowski, Associate Professor M. Dzeshka, Doctor H. Kishima, Doctor H. Arshad, Doctor J. Graby...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources